GenMont Biotech Inc
TWSE:3164

Watchlist Manager
GenMont Biotech Inc Logo
GenMont Biotech Inc
TWSE:3164
Watchlist
Price: 18.25 TWD -1.08% Market Closed
Market Cap: 1.6B TWD

Intrinsic Value

The intrinsic value of one GenMont Biotech Inc stock under the Base Case scenario is 14.97 TWD. Compared to the current market price of 18.25 TWD, GenMont Biotech Inc is Overvalued by 18%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
14.97 TWD
Overvaluation 18%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
GenMont Biotech Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about GenMont Biotech Inc?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is GenMont Biotech Inc valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for GenMont Biotech Inc.

Explain Valuation
Compare GenMont Biotech Inc to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Contacts
Loading...
How do you feel about GenMont Biotech Inc?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
GenMont Biotech Inc

Current Assets 504m
Receivables 44m
Other Current Assets 460m
Non-Current Assets 1.1B
Long-Term Investments 64m
PP&E 949m
Intangibles 2m
Other Non-Current Assets 60m
Current Liabilities 104m
Accounts Payable 6m
Short-Term Debt 21m
Other Current Liabilities 77m
Non-Current Liabilities 197m
Long-Term Debt 76m
Other Non-Current Liabilities 121m
Efficiency

Free Cash Flow Analysis
GenMont Biotech Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
GenMont Biotech Inc

Revenue
391.6m TWD
Cost of Revenue
-155m TWD
Gross Profit
236.6m TWD
Operating Expenses
-192.2m TWD
Operating Income
44.4m TWD
Other Expenses
-10m TWD
Net Income
34.4m TWD
Fundamental Scores

Profitability Score
Profitability Due Diligence

GenMont Biotech Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Sustainable 3Y Average Net Margin
Healthy Operating Margin
46/100
Profitability
Score

GenMont Biotech Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

GenMont Biotech Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
High Altman Z-Score
76/100
Solvency
Score

GenMont Biotech Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
GenMont Biotech Inc

There are no price targets for GenMont Biotech Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for GenMont Biotech Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one GenMont Biotech Inc stock?

The intrinsic value of one GenMont Biotech Inc stock under the Base Case scenario is 14.97 TWD.

Is GenMont Biotech Inc stock undervalued or overvalued?

Compared to the current market price of 18.25 TWD, GenMont Biotech Inc is Overvalued by 18%.

Back to Top